Felix Mueller
Clinical Researcher in Psychopharmacology
Papers
Trials
Key Impact
Noted for leading double-blind, placebo-controlled human studies of LSD that combine psychometrics and neuroimaging to characterise dose-dependent subjective effects and acute changes in brain network connectivity.
Background & Research
Felix Mueller is a clinical researcher in psychopharmacology affiliated with the Department of Psychiatry at the University of Basel, Switzerland, and a recurrent collaborator in Swiss and international programmes investigating classical psychedelics. His work primarily focuses on the acute behavioural and neural effects of lysergic acid diethylamide (LSD) in healthy volunteers, using double-blind, placebo-controlled designs and multimodal neuroimaging to probe dose–response relationships, emotion processing, social cognition and the neural correlates of hallucinations.
Mueller's contributions include several influential experimental studies documenting dose-dependent subjective and physiological responses to LSD, acute impairment of fear recognition alongside increases in emotional empathy and sociality, and neuroimaging findings implicating altered thalamic resting-state connectivity and changes in network hub dynamics as mechanisms underlying LSD-induced perceptual and affective alterations. He has collaborated widely with investigators specialising in clinical trial methodology, psychopharmacology and brain imaging (including Liechti, Dolder, Schmid and others) and has been involved in work informing Swiss limited medical use frameworks and clinician education for psychedelic-assisted therapies.